NanoString Technologies to Participate in the JMP

SEATTLE, June 11, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq: NSTG ), today announced that its management is scheduled to participate in the JMP Securities Healthcare Conference 2014 in New York.

NanoString management is scheduled to present on Wednesday, June 25, 2014 at 9:00 am ET. Interested parties can access the live audio webcast for this conference presentation at www.nanostring.com . The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 400 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna™ Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

For more information, please visit www.nanostring.com .

Investor Contact: Lynn Pieper of Westwicke Partners For NanoString Technologies 415-202-5678 Media Contact: Nicole Litchfield of Bioscribe Inc. For NanoString Technologies 415-793-6468